Some Drugs Can Only Be Made in Zero Gravity. A Japanese Startup Just Raised $40 Million to Build the Ship That Brings Them Back to Earth.

Some drugs can't be made on Earth.

The chemistry works. The biology is correct. The ingredients exist. But the moment you try to grow the precise crystal structure that defines a drug's molecular shape, gravity ruins it.

Convection currents. Sedimentation. The relentless pull of 9.8 m/s² dragging every molecule in the same direction — creating turbulence in a liquid that needs to be perfectly, impossibly still.

In orbit, none of that happens.

What Zero Gravity Actually Does to Chemistry

Protein crystallography is how pharmaceutical scientists map the exact 3D shape of a target molecule — a virus protein, a cancer receptor, a misfolded enzyme linked to Alzheimer's. If you know the shape with enough precision, you can design a drug that fits it like a key in a lock. Get the shape wrong by a fraction of a nanometer, and the drug doesn't work the way it should.

The problem: growing those crystals requires near-perfect conditions. On Earth, even in the most controlled laboratory in the world, gravity introduces imperfections. Microscopic convection currents. Density gradients. The crystals that grow in low Earth orbit — aboard the ISS, 420 km above your head — are measurably, structurally more perfect than anything that forms on the ground.

NASA has known this for decades. The ISS has hosted protein crystal growth experiments since the 1990s. The results consistently outperform anything grown on the ground. Researchers get better resolution on their molecular maps. Better resolution means better drug design.

But there was always the same problem.

Getting them back down.

A Japanese Startup Just Made That Problem Its Entire Business Model

ElevationSpace, a Japanese company led by CEO Ryohei Kobayashi, just closed a $40 million Series B funding round — bringing their total raised to $63.5 million. Their mission, in plain language: build a reentry capsule and recovery platform to bring manufactured goods from low Earth orbit back to Earth.

Not astronauts. Not museum samples. Products. The kind that pharmaceutical companies, materials scientists, and semiconductor researchers would actually pay for — things made in zero gravity because that's the only place they can be made correctly.

What Gets Made in Space That Can't Be Made on Earth

Let's get specific, because this is where it gets genuinely strange.

Protein crystals for drug discovery. Merck used ISS-grown crystals of Keytruda — one of the most important cancer immunotherapy drugs in the world — to improve its formulation. The crystals that grew in microgravity were more uniform and better defined than anything produced in a ground lab. The result: a subcutaneous injection formulation instead of a multi-hour IV infusion. That's not a laboratory curiosity. That changes how cancer patients receive treatment, week after week.

ZBLAN fiber optic cable. ZBLAN is a fluoride glass that transmits infrared light better than any silica fiber used on Earth today. The problem is straightforward: when it cools on the ground, convection caused by gravity creates crystalline defects that degrade performance. In space, it cools perfectly. ZBLAN fiber made in microgravity could be worth hundreds of times its weight per kilometer compared to conventional fiber. Multiple companies are already working on making it commercially.

Semiconductor wafers. Certain compound semiconductors — gallium arsenide, indium phosphide — form with fewer structural imperfections in microgravity. Fewer imperfections mean faster electron movement. Faster electrons mean more efficient chips.

America Already Proved This Works

In 2023, a US startup called Varda Space Industries launched a small spacecraft with one goal: crystallize ritonavir — an antiretroviral used in HIV treatment — in zero gravity, then bring the capsule back to Earth. After months in orbit and a lengthy regulatory process, the capsule landed in the Utah desert in early 2024.

The crystalline structure they recovered was different from anything producible on the ground. More uniform. More controlled. Exactly the kind of result pharmaceutical companies spend decades and billions trying to achieve in terrestrial laboratories — and they got it on a first attempt.

The proof of concept is no longer theoretical. The question now is who builds the infrastructure to do it at scale. That's the race ElevationSpace just raised $40 million to win — on behalf of Japan, and for the Asia-Pacific market that no American company is yet positioned to serve. You can watch the orbital environment they're designing for using the SkyLens live tracker.

The Clock Everyone Is Ignoring

Here's the detail that makes all of this genuinely urgent.

The International Space Station retires in 2030. NASA plans to deliberately deorbit it — firing its engines to send it into the ocean in a controlled reentry. The world's only continuously operated microgravity research facility, running without interruption since the year 2000, is going away in less than four years.

Private space stations are supposed to fill the gap. Axiom Space is already attaching commercial modules to the ISS. Starlab and Blue Origin's Orbital Reef have development contracts. But none of them are operational. There will be a gap — and in that gap, the supply chain for orbital manufacturing either exists or it doesn't.

ElevationSpace is designing a reentry capsule that can work with whatever platform is available: the ISS while it operates, future commercial stations after it's gone. The specific platform is secondary. The capability — bring manufactured products from orbit to ground, reliably and affordably — is what the market needs.

Why Japan, and Why This Matters Beyond Japan

Japan has operated the Kibo module on the ISS since 2009 — one of the largest and most capable laboratory modules on the station. JAXA has decades of microgravity research experience. The country already has the scientific infrastructure. ElevationSpace is the commercial layer being built on top of it.

The $40 million Series B is not an idea being funded. It's a working concept being scaled. Investors who fund at this stage expect a real customer pipeline. Learn more about how low Earth orbit works and what makes altitude so significant on SkyLens's explainer pages.

What This Actually Changes

The strange thing about microgravity manufacturing is how it reframes what we thought was fixed. We built science around the assumption that physics is constant everywhere, that a lab in Tokyo and a lab in Houston and a lab in Geneva all operate under the same rules. They don't.

400 km above your head, the rules change. Crystals grow without turbulence. Metals cool without convection. Proteins fold without the constant pull of mass toward the floor. That difference — that 420-kilometer altitude difference — is the entire premise of a new manufacturing sector.

ElevationSpace wants to build the logistics infrastructure to exploit that difference commercially. Japan is funding it. The ISS has already proven the science works. And the window to get this right before the world's only operational platform deorbits into the Pacific is shorter than most people realize.

The question was never whether manufacturing in orbit is possible. The question is who builds the return trip first. Read more stories on SkyLens as this industry develops.